Portal de Periódicos da CAPES

Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study

2022; Multidisciplinary Digital Publishing Institute; Volume: 14; Issue: 17 Linguagem: Inglês

10.3390/cancers14174142

2072-6694

Alessandro Rizzo, Veronica Mollica, Andrea Marchetti, Giacomo Nuvola, Matteo Rosellini, Elisa Tassinari, Javier Molina‐Cerrillo, Zin Myint, Tomáš Büchler, Fernando Sabino Marques Monteiro, Enrique Grande, Matteo Santoni, Francesco Massari,

Colorectal and Anal Carcinomas

Adjuvant treatment has always been a cornerstone in the therapeutic approach of many cancers, considering its role in reducing the risk of relapse and, in some cases, increasing overall survival. Adjuvant immune checkpoint inhibitors have been tested in different malignancies.